[The molecular diagnosis of cancer].
Cancer is considered a genetic disease, being classified as an accumulative somatic disorder aside of the Mendelian diseases, the chromosomopaties and the multifactorial diseases. It has been demonstrated in several human cancers that specific mutations in some genes are related to hystopathologic features and tumor progression. Thereby, mutations represent potentially valuable markers in disease-stage detection and evaluation. Mutations associated with neoplasia development and evolution are very valuable, and the related genes are classified as: oncogenes, tumor suppressing genes, DNA repairing genes and cell cycle regulator genes. The factability to determine and characterize these genes and relate them with one or several steps of tumorogenesis, makes them molecular markers that let us predict risk, make an early diagnosis, confirm a diagnosis, establish prognosis, guide the therapy and determine resistance to treatments. Molecular methods used today for analysis of this markers offer great advantages: they are vary sensitive, use a small sample, are fast, can be easily automated, are easily interpreted, allows quantitations and, very importantly, they become cheaper when a large quantity of samples are handled. In this review we mention some types of cancers and molecular methods that can be used to take advantage of their biomarkers.